ViaLase receives CE mark for femtosecond laser to treat glaucoma
Click Here to Manage Email Alerts
The ViaLase laser received a CE mark for the treatment of adults with primary open-angle glaucoma, according to a press release.
The device combines a femtosecond laser with image guidance to deliver femtosecond laser, image-guided, high-precision trabeculotomy, also known as FLigHT, the release said.
“ViaLase is thrilled to have received CE mark approval for our ViaLase laser in Europe,” Tibor Juhasz, PhD, founder and CEO of ViaLase, told Healio in an email. “It’s an exciting achievement that puts ViaLase on the path to commercialization in Europe in early 2025. We look forward to soon bringing this groundbreaking technology, which has the potential to deliver surgery-like results without the need for opening the eye, to physicians and glaucoma patients in Europe.”
The company also announced strategic distribution partnerships with Teleon Surgical in Germany and Austria and Global Surgical Service in Portugal and Spain to prepare for a selective commercial rollout of the laser later this year. The laser is not approved in the U.S.
Juhasz reports being the founder and CEO of ViaLase.
Read more about
Click Here to Manage Email Alerts